FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Menold Daniel
2. Date of Event Requiring Statement (Month/Day/Year)
04/27/2017
3. Issuer Name and Ticker or Trading Symbol
CymaBay Therapeutics, Inc. [CBAY]
(Last)
(First)
(Middle)
C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD., SUITE 130
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Vice President, Finance
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEWARK, CA 94560
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (1) 01/21/2024 Common Stock 19,459 $ 5 D  
Stock Option (right to buy)   (1) 01/06/2025 Common Stock 7,000 $ 10 D  
Stock Option (right to buy)   (1) 01/25/2026 Common Stock 8,500 $ 1.06 D  
Stock Option (right to buy)   (2) 07/24/2026 Common Stock 1,545 $ 1.82 D  
Stock Option (right to buy)   (1) 01/18/2027 Common Stock 15,000 $ 1.72 D  
Stock Appreciation Right   (3) 01/21/2024 Common Stock 6,486 $ 5 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Menold Daniel
C/O CYMABAY THERAPEUTICS, INC.
7999 GATEWAY BLVD., SUITE 130
NEWARK, CA 94560
      Vice President, Finance  

Signatures

/s/ Daniel Menold 05/05/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares subject to the option shall become vested and exercisable according to the following schedule: 25% of the shares subject to the option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in equal monthly installments over the next 36 months.
(2) The shares subject to the option shall become vested and exercisable according to the following schedule: 25% of the shares subject to the option shall vest on July 22, 2017, and the remaining shares shall vest in equal monthly installments over the next 36 months.
(3) This incentive award (the "Award") was granted under the Issuer's 2013 Equity Incentive Plan and can be settled in cash or shares of the Issuer's common stock, at the sole discretion of the Issuer. The shares subject to the Award shall vest in 48 equal monthly installments from the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.